- Home
- EXPD vs GMAB Comparison
EXPD vs GMAB Comparison
Compare EXPD & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXPD
- GMAB
- Stock Information
- Founded
- EXPD 1979
- GMAB 1999
- Country
- EXPD United States
- GMAB Denmark
- Employees
- EXPD N/A
- GMAB N/A
- Industry
- EXPD Oil Refining/Marketing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EXPD Consumer Discretionary
- GMAB Health Care
- Exchange
- EXPD Nasdaq
- GMAB Nasdaq
- Market Cap
- EXPD 15.3B
- GMAB 15.4B
- IPO Year
- EXPD N/A
- GMAB N/A
- Fundamental
- Price
- EXPD $121.10
- GMAB $27.54
- Analyst Decision
- EXPD Sell
- GMAB Buy
- Analyst Count
- EXPD 10
- GMAB 6
- Target Price
- EXPD $114.11
- GMAB $37.60
- AVG Volume (30 Days)
- EXPD 1.1M
- GMAB 1.4M
- Earning Date
- EXPD 11-04-2025
- GMAB 11-05-2025
- Dividend Yield
- EXPD 1.26%
- GMAB N/A
- EPS Growth
- EXPD 31.92
- GMAB 77.72
- EPS
- EXPD 6.14
- GMAB 21.62
- Revenue
- EXPD $11,273,140,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- EXPD $2.35
- GMAB $22.68
- Revenue Next Year
- EXPD $0.65
- GMAB $15.85
- P/E Ratio
- EXPD $19.81
- GMAB $1.27
- Revenue Growth
- EXPD 23.70
- GMAB 32.97
- 52 Week Low
- EXPD $100.47
- GMAB $17.24
- 52 Week High
- EXPD $131.59
- GMAB $27.62
- Technical
- Relative Strength Index (RSI)
- EXPD 55.75
- GMAB 78.40
- Support Level
- EXPD $119.38
- GMAB $24.75
- Resistance Level
- EXPD $123.13
- GMAB $27.61
- Average True Range (ATR)
- EXPD 2.02
- GMAB 0.36
- MACD
- EXPD -0.13
- GMAB 0.32
- Stochastic Oscillator
- EXPD 59.24
- GMAB 98.37
About EXPD Expeditors International of Washington Inc.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.